Zan Shen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6192426/publications.pdf

Version: 2024-02-01

65 papers	1,246 citations	18 h-index	395702 33 g-index
69	69	69	1923
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment. Molecular Therapy, 2022, 30, 1188-1200.	8.2	19
2	Ailanthone Inhibits Proliferation, Migration and Invasion of Osteosarcoma Cells by Downregulating the Serine Biosynthetic Pathway. Frontiers in Oncology, 2022, 12, 842406.	2.8	4
3	A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma. Frontiers in Cell and Developmental Biology, 2022, 10, 859958.	3.7	5
4	Fibrinogen–Albumin Ratio Index Exhibits Predictive Value of Neoadjuvant Chemotherapy in Osteosarcoma. Cancer Management and Research, 2022, Volume 14, 1671-1682.	1.9	3
5	Chromatin accessibility of CD8 T cell differentiation and metabolic regulation. Cell Biology and Toxicology, 2021, 37, 367-378.	5.3	6
6	Clinical significance of indeterminate pulmonary nodules on the survival of 364 patients with nonmetastatic, highâ€grade, localized osteosarcoma: A 12â€year retrospective cohort study. Journal of Surgical Oncology, 2021, 123, 587-595.	1.7	5
7	Impacts of Pharmacists-Managed Oncology Outpatient Clinic on Resolving Drug-Related Problems in Ambulatory Neoplasm Patients: A Prospective Study in China. Inquiry (United States), 2021, 58, 004695802110096.	0.9	1
8	Impact of Secondary Aneurysmal Bone Cysts on Survival of Patients with Enneking Stage IIB Extremity Osteosarcoma: A Propensity Score Matching Analysis. Annals of Surgical Oncology, 2021, 28, 7864-7872.	1.5	1
9	The effectiveness of an independent anti-neoplastic medication therapy management system in ambulatory cancer patients. Translational Cancer Research, 2021, 10, 1703-1711.	1.0	1
10	Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden. Frontiers in Endocrinology, 2021, 12, 625226.	3.5	5
11	The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma. OncoTargets and Therapy, 2021, Volume 14, 213-220.	2.0	2
12	The timing of targeted therapy initiation in metastatic sarcoma as an adjuvant to first-line chemotherapy or a second-line agent. American Journal of Translational Research (discontinued), 2021, 13, 9095-9103.	0.0	0
13	A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. Cell Biology and Toxicology, 2021, , 1.	5.3	5
14	N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. EBioMedicine, 2020, 59, 102955.	6.1	61
15	TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1. Journal of Experimental and Clinical Cancer Research, 2020, 39, 23.	8.6	24
16	FAT1 and MSH2 Are Predictive Prognostic Markers for Chinese Osteosarcoma Patients Following Chemotherapeutic Treatment. Journal of Bone and Mineral Research, 2020, 37, 885-895.	2.8	2
17	Significance of HIFU in local unresectable recurrence of soft tissue sarcoma, a single-center, respective, case series in China. Surgical Oncology, 2019, 30, 117-121.	1.6	5
18	Clinical Practice Guideline for Image-Guided Multimode Tumour Ablation Therapy in Hepatic Malignant Tumours. Current Oncology, 2019, 26, 658-664.	2.2	7

#	Article	IF	CITATIONS
19	MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen. International Journal of Oncology, 2019, 54, 2019-2029.	3.3	5
20	Bufalin suppresses the migration and invasion of prostate cancer cells through HOTAIR, the sponge of miR-520b. Acta Pharmacologica Sinica, 2019, 40, 1228-1236.	6.1	45
21	<scp>SKA</scp> 1 induces <i>deÂnovo </i> <scp>MTX</scp> â€resistance in osteosarcoma through inhibiting <scp>FPGS</scp> transcription. FEBS Journal, 2019, 286, 2399-2414.	4.7	6
22	Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clinical and Translational Oncology, 2019, 21, 1624-1633.	2.4	34
23	Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. BMC Cancer, 2019, 19, 1168.	2.6	10
24	H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma. British Journal of Cancer, 2018, 118, 522-533.	6.4	17
25	Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. Scientific Reports, 2018, 8, 8537.	3.3	50
26	DGKZ Acts as a Potential Oncogene in Osteosarcoma Proliferation Through Its Possible Interaction With ERK1/2 and MYC Pathway. Frontiers in Oncology, 2018, 8, 655.	2.8	12
27	Promotion of proliferation and inhibition of apoptosis by diacylglycerol kinase zeta, a potential oncogene of osteosarcoma. Journal of Clinical Oncology, 2018, 36, e23503-e23503.	1.6	0
28	Impact of first-line treatment on outcomes of Ewing sarcoma of the spine. American Journal of Cancer Research, 2018, 8, 1262-1272.	1.4	4
29	Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model. BMC Cancer, 2017, 17, 126.	2.6	21
30	Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro. Biological Research, 2017, 50, 15.	3.4	21
31	Safety and efficacy of multilevel vertebroplasty for painful osteolytic spinal metastases: a single-centre experience. European Radiology, 2017, 27, 3436-3442.	4.5	14
32	Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients. Scientific Reports, 2017, 7, 17480.	3.3	13
33	Elevated expression of serine/threonine phosphatase type 5 correlates with malignant proliferation in human osteosarcoma Acta Biochimica Polonica, 2017, 64, 11-16.	0.5	4
34	Apatinib for patients with unresectable high-grade osteosarcoma progressing after standard chemotherapy: A multi-center retrospective study Journal of Clinical Oncology, 2017, 35, 11031-11031.	1.6	2
35	Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis. PLoS ONE, 2017, 12, e0174668.	2.5	5
36	Symptom interval of osteosarcoma around the knee joint: an analysis of 82 patients of a single institute. European Journal of Cancer Care, 2016, 25, 849-854.	1.5	7

#	Article	IF	CITATIONS
37	Prognostic value of inflammation-based scores in patients with osteosarcoma. Scientific Reports, 2016, 6, 39862.	3.3	67
38	Bilateral spontaneous pneumothorax in an osteosarcoma patient with pulmonary metastases: A case report. Oncology Letters, 2016, 11, 1179-1180.	1.8	9
39	Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis. Molecular Therapy, 2016, 24, 1358-1368.	8.2	37
40	Relationship Between HSP70 and ERBB2 Expression in Breast Cancer Cell Lines Regarding Drug Resistance. Anticancer Research, 2016, 36, 1243-9.	1.1	7
41	Heterogeneous expression and biological function of ubiquitin carboxy-terminal hydrolase-L1 in osteosarcoma. Cancer Letters, 2015, 359, 36-46.	7.2	26
42	Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology, 2015, 26, 1766-1771.	1.2	257
43	CD133 ⁺ CD44 ⁺ Cells Mediate in the Lung Metastasis of Osteosarcoma. Journal of Cellular Biochemistry, 2015, 116, 1719-1729.	2.6	30
44	Accuracy of Tokuhashi score system in predicting survival of lung cancer patients with vertebral metastasis. Journal of Neuro-Oncology, 2015, 125, 427-433.	2.9	10
45	High-intensity focused ultrasound: Noninvasive treatment for local unresectable recurrence of osteosarcoma. Surgical Oncology, 2015, 24, 9-15.	1.6	36
46	Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter?. Medical Oncology, 2015, 32, 307.	2.5	5
47	Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma. American Journal of Cancer Research, 2015, 5, 411-22.	1.4	3
48	Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute. Oncology Letters, 2014, 8, 2243-2248.	1.8	5
49	Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. Critical Reviews in Oncology/Hematology, 2014, 92, 71-82.	4.4	60
50	Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2014, 89, 394-403.	4.4	62
51	Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis. European Journal of Cancer, 2014, 50, 1125-1136.	2.8	17
52	Stereotactic radiosurgery, a potential alternative treatment for pulmonary metastases from osteosarcoma. International Journal of Oncology, 2014, 44, 1091-1098.	3.3	25
53	KLF8 knockdown suppresses proliferation and invasion in human osteosarcoma cells. Molecular Medicine Reports, 2014, 9, 1613-1617.	2.4	19
54	Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells. Molecular Medicine Reports, 2014, 10, 2985-2992.	2.4	6

#	Article	IF	CITATIONS
55	Comparison of pirarubicin-based versus gemcitabine–docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. International Journal of Clinical Oncology, 2013, 18, 498-505.	2.2	17
56	Retrospective analysis of prognostic factors for sixty osteosarcoma patients with local recurrence. Chinese-German Journal of Clinical Oncology, 2013, 12, 123-128.	0.1	0
57	Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacologica Sinica, 2012, 33, 832-838.	6.1	17
58	CT Fluoroscopy-guided Percutaneous Osteoplasty for the Treatment of Osteolytic Lung Cancer Bone Metastases to the Spine and Pelvis. Journal of Vascular and Interventional Radiology, 2012, 23, 1135-1142.	0.5	28
59	Evaluation of pirarubicin–cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Medical Oncology, 2012, 29, 2229-2233.	2.5	12
60	Retrospective clinical analysis of MAID protocol as first-line treatment on 137 metastatic soft-tissue sarcomas patients. Chinese-German Journal of Clinical Oncology, 2012, 11, 117-120.	0.1	2
61	Comparison between preadolescent and adolescent patients with high-grade osteosarcoma in China. Chinese-German Journal of Clinical Oncology, 2012, 11, 274-278.	0.1	3
62	Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 270-275.	1.1	20
63	Expression levels of CXCR4 and VEGF correlate with blood-borne metastatic progression and outcome in patients with osteosarcoma. Chinese-German Journal of Clinical Oncology, 2009, 8, 292-295.	0.1	O
64	Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma. Current Therapeutic Research, 2009, 70, 150-160.	1.2	17
65	A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma. Cancer Letters, 2008, 272, 268-276.	7.2	15